D. Boral Capital reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.
Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a research note on Tuesday, November 19th.
Get Our Latest Stock Report on ANIX
Anixa Biosciences Stock Performance
Anixa Biosciences (NASDAQ:ANIX – Get Free Report) last released its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. As a group, sell-side analysts anticipate that Anixa Biosciences will post -0.42 earnings per share for the current year.
Institutional Investors Weigh In On Anixa Biosciences
Large investors have recently bought and sold shares of the stock. Concorde Asset Management LLC acquired a new position in shares of Anixa Biosciences during the second quarter valued at about $31,000. Virtu Financial LLC acquired a new position in Anixa Biosciences during the 3rd quarter worth approximately $34,000. Westside Investment Management Inc. raised its stake in Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after buying an additional 21,100 shares during the period. Tyler Stone Wealth Management boosted its holdings in Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after acquiring an additional 21,008 shares in the last quarter. Finally, International Assets Investment Management LLC grew its stake in Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after acquiring an additional 23,800 shares during the period. 29.13% of the stock is currently owned by institutional investors and hedge funds.
Anixa Biosciences Company Profile
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.
Featured Articles
- Five stocks we like better than Anixa Biosciences
- 3 Small Caps With Big Return Potential
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Overbought Stocks Explained: Should You Trade Them?
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.